As elucidated by Wu and colleagues, TREM-1+ TAMs promote the recruitment of CCR6+Foxp3+ Tregs through the ERK/NF-κB axis, which endows HCC with anti-PD-L1 therapy resistance (61). The gene discussed is NFKB1; the disease is hepatocellular carcinoma.